Valuation: Evotec SE

Market Cap 61Cr 70Cr 57Cr 52Cr 98Cr 6.73TCr 100Cr 679.26Cr 264.95Cr 3.28TCr 261Cr 255.36Cr 11TCr P/E 2026 *
-4.02x
P/E 2027 * -10x
Enterprise Value 65Cr 74Cr 61Cr 56Cr 104.62Cr 7.19TCr 106.5Cr 725.36Cr 282.93Cr 3.51TCr 278.72Cr 272.69Cr 12TCr EV / Sales 2026 *
1.09x
EV / Sales 2027 * 0.97x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 week-1.20%
Current month-30.69%
1 month-25.82%
3 months-39.07%
6 months-44.04%
Current year-36.44%
1 week 3.38
Extreme 3.38
3.67
1 month 3.18
Extreme 3.176
5.23
Current year 3.18
Extreme 3.176
6.73
1 year 3.18
Extreme 3.176
7.84
3 years 3.18
Extreme 3.176
24.44
5 years 3.18
Extreme 3.176
45.83
10 years 3.18
Extreme 3.176
45.83
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 43 22/06/2022
Date Insider Type Main position Quantity % Market Cap.
15/06/26 Sell

Chief Technology Officer

-1,19,900 0.0674%
20/05/26 Fiscal year

Chief Technology Officer

12,462 0.0070%
04/05/26 Buy 15,510 0.0087%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-1.20%-44.40%-85.34% 70Cr
+1.08%-6.74%-2.31%+10.45% 4.61TCr
+3.13%+5.31%+402.77%+627.41% 3.89TCr
+2.14%+2.79%+10.66%+67.11% 3.56TCr
+4.43%-1.56%+6.67%-9.18% 3.31TCr
+1.23%-1.99%-0.05%+30.76% 2.64TCr
+0.29%-2.77% - - 1.66TCr
+14.71%+12.60%+38.47%+145.28% 1.51TCr
-6.32%-4.59%+4.36%+8.22% 1.41TCr
+1.82%+0.14%+1.39%-29.84% 1.28TCr
Average +2.30%-2.04%+46.40%+84.98% 2.39TCr
Weighted average by Cap. +2.55%-2.47%+75.39%+133.12%

Financials

2026 *2027 *
Net sales 60Cr 68Cr 56Cr 51Cr 96Cr 6.6TCr 98Cr 666.16Cr 259.84Cr 3.22TCr 255.97Cr 250.43Cr 11TCr 74Cr 84Cr 68Cr 63Cr 117.95Cr 8.11TCr 120.06Cr 817.75Cr 318.96Cr 3.95TCr 314.22Cr 307.42Cr 14TCr
Net income -15Cr -17Cr -14Cr -13Cr -24Cr -1.62TCr -24Cr -163.49Cr -64Cr -790.39Cr -63Cr -61Cr -2.74TCr -4.75Cr -5.4Cr -4.41Cr -4.05Cr -7.6Cr -522.53Cr -7.74Cr -53Cr -21Cr -254.87Cr -20Cr -20Cr -884.21Cr
Net Debt 4.15Cr 4.72Cr 3.86Cr 3.55Cr 6.65Cr 456.96Cr 6.77Cr 46Cr 18Cr 222.88Cr 18Cr 17Cr 773.25Cr 11Cr 12Cr 9.77Cr 8.99Cr 17Cr 1.16TCr 17Cr 116.83Cr 46Cr 564.82Cr 45Cr 44Cr 1.96TCr
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,526
Date Price Change Volume
23/26/23 3.464 +0.06% 7,38,743
22/26/22 €3.462 -2.04% 6,94,004
21/26/21 €3.534 -0.62% 12,36,552
20/26/20 €3.556 +3.37% 10,76,058
17/26/17 €3.440 -0.64% 14,17,956
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
3.464EUR
Average target price
4.900EUR
Spread / Average Target
+41.45%

Quarterly revenue - Rate of surprise